# A Study to Determine the Correct Dose of Amikacin Which is Delivered Directly to the Lungs of Ventilated Patients as an Aerosol Via an Investigational Device Called the Pulmonary Delivery Device System (PDDS)

> **NCT01004445** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 69 (actual)

## Conditions studied

- Pneumonia

## Interventions

- **DRUG:** Amikacin (BAY41-6551)
- **DRUG:** Amikacin (BAY41-6551)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01004445
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2006-06
- **Final completion:** 2006-06
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2011-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01004445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01004445, "A Study to Determine the Correct Dose of Amikacin Which is Delivered Directly to the Lungs of Ventilated Patients as an Aerosol Via an Investigational Device Called the Pulmonary Delivery Device System (PDDS)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01004445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*